Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
Basic and Clinical Pharmacology and Toxicology(2)
Drug Safety(1)
Frontiers in Pharmacology(1)
International Journal of Environmental Research and Public Health(1)
Journal of Pharmaceutical Health Services Research(1)
Área temáticas
Farmacología y terapéutica(5)
Problemas sociales y servicios a grupos(3)
Enfermedades(2)
Salud y seguridad personal(2)
Derecho(1)
Origen
scopus(8)
Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study
ArticleAbstract: Background: In May 2020, the ACCESS (The vACCine covid-19 monitoring readinESS) project was launchedPalabras claves:Adverse events of special interest, Background rates, covid-19, Vaccine safetyAutores:Aragón M., Barbieri E., Bartolini C., Bryant V., Carlos E. Durán, Carreras J.J., de Burgos A., Diez-Domingo J., Dodd C., Ehrenstein V., Elbers R.J.H.J., García-Poza P., Giaquinto C., Gini R., Haug U., Huerta C., Kahlert J., Klungel O.H., Martín-Pérez M., Martínez-González M., Mira-Iglesias A., Pallejà-Millán M., Paoletti O., Schink T., Souverein P., Stona L., Sturkenboom M.C.J.M., Thurin N.H., Vergara-Hernández C., Villalobos F., Wang L., Weibel D., Willame C.Fuentes:scopusAnticholinergic Exposure in a Cohort of Adults Aged 80 years and Over: Associations of the MARANTE Scale with Mortality and Hospitalization
ArticleAbstract: Anticholinergics are frequently prescribed for older adults and can lead to adverse drug events. ThePalabras claves:Autores:Azermai M., Carlos E. Durán, Christiaens T., Dalleur O., Degryse J., Elseviers M., Klamer T., Vaes B., Vander Stichele R., Wauters M.Fuentes:scopusA Novel Scale Linking Potency and Dosage to Estimate Anticholinergic Exposure in Older Adults: the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale
ArticleAbstract: Quantification of the anticholinergic exposure insufficiently or imprecisely incorporates dosage infPalabras claves:Autores:Azermai M., Carlos E. Durán, Christiaens T., Elseviers M., Klamer T., Vander Stichele R., Wauters M.Fuentes:scopusCorrection to: A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project (Drug Safety, (2022), 45, 4, (333-344), 10.1007/s40264-022-01154-7)
OtherAbstract: In the original version of this article, the given and family names of “Leonardo Roque Pereira” werePalabras claves:Autores:Carlos E. Durán, Kontogiorgis C., Lalagkas P.N., Layton D., Pereira L.R., Poulentzas G., Sturkenboom M.C.J.M.Fuentes:scopusEssential medicines in universal health coverage: A scoping review of public health law interventions and how they are measured in five middle-income countries
ArticleAbstract: Very few studies exist of legal interventions (national laws) for essential medicines as part of uniPalabras claves:access to medicines, drug, Essential medicines, health insurance, Health services accessibility, Insurance, Legislation, Middle income country, Pharmaceutical policy, Pharmaceutical services, universal health coverage, Universal health insuranceAutores:Ackon A., Alexandrov N.V., Babar Z.U.D., Brutsaert D., Carlos E. Durán, Demchenko I., El-Dahiyat F., Hafidz F., Haque R., Hussain R., Perehudoff K., Salenga R., Suleman F.Fuentes:scopusEMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
OtherAbstract:Palabras claves:Autores:Cañás M., Carlos E. Durán, Chistiaens T.Fuentes:scopusMyocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries
ArticleAbstract: Background: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary wPalabras claves:adverse drug reaction, COVID-19 Vaccine, myocarditis , Pericarditis, pharmacovigilanceAutores:Alsina E., Aragón M., Belitser S.V., Bots S.H., Carlos E. Durán, Douglas I.J., García-Poza P., Gini R., Herings R.M.C., Huerta C., Klungel O.H., Martin I., Martín-Pérez M., Messina D., Overbeek J.A., Pallejà-Millán M., Paoletti O., Riera-Arnau J., Schultze A., Sisay M.M., Souverein P., Sturkenboom M.C.J.M., Swart K.M.A., Villalobos F.Fuentes:scopusSharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010–2014) consumption of oncologic drugs in public and private hospitals
ArticleAbstract: Objective: In Ecuador, a new constitutional mandate (2008) allowed the government to implement freePalabras claves:Cáncer, drug utilization, ECUADOR, health expenditures, Latin America, molecular targeted therapy, oncologic drugsAutores:Carlos E. Durán, Christiaens T., Elseviers M., Rottey S., Vander Stichele R.Fuentes:scopus